Lead Optimization and Modulation of hERG Activity in a Series of Aminooxazoline Xanthene beta-Site Amyloid Precursor Protein Cleaving Enzyme (BACE1) Inhibitors.
Epstein, O., Bryan, M.C., Cheng, A.C., Derakhchan, K., Dineen, T.A., Hickman, D., Hua, Z., Human, J.B., Kreiman, C., Marx, I.E., Weiss, M.M., Wahl, R.C., Wen, P.H., Whittington, D.A., Wood, S., Zheng, X.M., Fremeau, R.T., White, R.D., Patel, V.F.(2014) J Med Chem 57: 9796-9810
- PubMed: 25389560 
- DOI: https://doi.org/10.1021/jm501266w
- Primary Citation of Related Structures:  
4RCE, 4RCF - PubMed Abstract: 
The optimization of a series of aminooxazoline xanthene inhibitors of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) is described. An early lead compound showed robust Aβ lowering activity in a rat pharmacodynamic model, but advancement was precluded by a low therapeutic window to QTc prolongation in cardiovascular models consistent with in vitro activity on the hERG ion channel ...